Retatrutide (LY3437943) — Triple GLP-1/GIP/Glucagon Receptor Agonist | Phase 3 Investigational Research Compound

GLP-1R — Satiety Signaling and Glucose-Dependent Insulin Release

GLP-1R is a class B G-protein-coupled receptor expressed on pancreatic beta cells and on neurons in the hypothalamic arcuate nucleus and area postrema. Agonism drives cAMP accumulation through Gs coupling, which potentiates glucose-dependent insulin secretion — the insulin response scales with ambient glucose rather than firing unconditionally, which is why GLP-1R agonists carry a low intrinsic hypoglycemia signal on their own.

The central arm is the one that dominates the body-weight literature. GLP-1R activation in the hindbrain and hypothalamus suppresses food intake and slows gastric emptying. It is also the arm responsible for most of the gastrointestinal tolerability burden reported across the incretin class — nausea and vomiting track GLP-1R exposure more closely than they track the other two receptors.

GIPR — Adipocyte Signaling and Tolerability Offset

GIPR is the receptor for glucose-dependent insulinotropic polypeptide, expressed on beta cells, on adipocytes, and in CNS regions overlapping GLP-1R territory. Beta-cell GIPR agonism adds a second glucose-dependent insulinotropic input. Adipocyte GIPR signaling influences lipid buffering and nutrient partitioning, which is a different lever on adiposity than appetite suppression.

GIPR is also where the field openly disagrees with itself. Both GIPR agonists and GIPR antagonists produce weight loss in preclinical models, and the mechanism reconciling those two observations has not been settled — one reading is that sustained agonism functionally desensitizes the receptor, another is that central and peripheral GIPR populations pull in opposite directions. Retatrutide sits on the agonist side of that argument. Researchers designing GIPR-focused work should read the antagonist literature before assuming the direction of effect is established.

A practical consequence reported in the incretin literature: GIPR agonism appears to blunt some of the nausea associated with GLP-1R activation, which is part of why dual and triple agonists have been titrated to GLP-1R exposures that would be poorly tolerated by a GLP-1R-only compound.

GCGR — Energy Expenditure and Hepatic Lipid Handling

GCGR agonism is the addition that separates retatrutide from tirzepatide. Glucagon receptor activation raises resting energy expenditure, promotes lipolysis in adipose tissue, and increases hepatic fatty-acid oxidation. Where GLP-1R and GIPR act mainly on the intake side of energy balance, GCGR acts on the expenditure side — a genuinely different mechanism rather than a stronger version of the same one.

Glucagon also raises hepatic glucose output, which on its own would work against glycemic control. The design premise of the triple agonist is that concurrent GLP-1R and GIPR agonism supplies enough insulinotropic counter-pressure to hold glucose in range while the glucagon arm contributes to energy expenditure. Whether that balance holds across a broad and unselected population, over years rather than months, is exactly what Phase 3 exists to answer.

What the Combined Pharmacology Has and Has Not Shown

The most complete public dataset on the combination is Jastreboff and colleagues' Phase 2 trial published in the New England Journal of Medicine in 2023. In that trial, participants in the highest-dose arm showed a mean body-weight reduction of approximately 24% at 48 weeks. That figure is a published clinical finding cited here for pharmacological context, and it describes trial participants receiving an investigational drug product under medical supervision — it is not a claim about any research-market material and not a claim about any outcome for a purchaser.

Phase 2 is not Phase 3. The 2023 trial enrolled a few hundred participants under selection criteria narrower than a marketed indication would carry, ran for under a year, and was powered for weight change rather than for the durability, cardiovascular, and rare-event questions that determine approval. Two PMC reviews summarize the efficacy and safety picture as it stood before Phase 3 readouts, and both are worth reading alongside the primary trial rather than in place of it.

One more gap worth naming: Lilly has not publicly disclosed retatrutide's full amino-acid sequence, and no molecular formula appears in the public entity record. The molecular weight (4,731 Da) and CAS registry number (2381089-83-2) are established; the primary structure is not public. For a research buyer this is not academic — mass confirmation against 4,731 Da by LC-MS/MS is the identity check available, and sequence-level verification is not, for anyone.

Energy Balance and Metabolic Signaling Models

• ·Hepatic lipid handling: GCGR-driven fatty-acid oxidation is the mechanistic basis for the hepatic steatosis endpoints that appear across the triple-agonist literature.
• ·Thermogenesis and expenditure readouts: indirect calorimetry in rodent models separates the expenditure contribution of GCGR agonism from the intake suppression driven by GLP-1R.
• ·Glucose-dependent insulin secretion: isolated islet preparations measure the insulinotropic arms of GLP-1R and GIPR against the counter-regulatory hepatic effect of GCGR.

Analytical and Quality-Control Method Development

• ·Reverse-phase HPLC method development: fatty-acylated peptides of this size have distinctive retention behavior, and retatrutide is used in developing separation methods for acylated analogs.
• ·LC-MS/MS identity confirmation: mass confirmation against 4,731 Da is the working identity assay for a compound whose primary structure is not publicly disclosed.
• ·Stability and degradation profiling: lyophilized-versus-reconstituted stability studies on acylated incretin analogs, where aggregation rather than hydrolysis is usually the failure mode.